-
Product Name
Anti-DOPA Decarboxylase/DDC antibody
- Documents
-
Description
Rabbit monoclonal to DOPA Decarboxylase/DDC
-
Tested applications
ELISA, IHC-P
-
Species reactivity
Human DOPA Decarboxylase / DDC
-
Alternative names
AADC antibody; Aadc antibody; Aadc antibody; AADC antibody; Ddc antibody; DDC antibody; DOPA Decarboxylase antibody; DOPA Decarboxylase antibody; RP23-373H2.3 antibody
- Immunogen
-
Isotype
Rabbit IgG
-
Preparation
This antibody was obtained from a rabbit immunized with purified, recombinant Human DOPA Decarboxylase / DDC (rh DOPA Decarboxylase / DDC; NP_000781.1; Met 1-Glu 480).
-
Clonality
Monoclonal
-
Formulation
0.2 μm filtered solution in PBS with 5% trehalose
-
Storage instructions
This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles. -
Applications
ELISA: 0.1-0.2 μg/mL
This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human DDC.
IHC-P: 5-10 μg/mL
-
Validations
DOPA Decarboxylase / DDC Antibody, Rabbit MAb, Immunohistochemistry
Immunochemical staining of human DDC in human brain with rabbit monoclonal antibody (5 µg/mL, formalin-fixed paraffin embedded sections). The left panel: tissue incubated with primary antibody; The right panel: tissue incubated with the mixture of primary antibody and antigen (recombinant protein).
-
Background
Dopa Decarboxylase (DDC), also known as AADC and Aromatic-L-amino acid decarboxylase, is a 54 kDa member of the group II decarboxylase family of proteins.It is a vitamin B6-dependent homodimeric enzyme that catalyzes the decarboxylation of both L-3,4-dihydroxyphenylalanine (L-DOPA) and L-5-hydroxytryptophan to dopamine and serotonin, respectively, which are major mammalian neurotransmitters and hormones belonging to catecholamines and indoleamines. Since L-DOPA is regularly used to treat the symptoms of Parkinson's disease, the catalytic pathway is of particular research interest. Defects of DDC are associated with severe developmental delay, oculogyric crises (OGC), as well as autosomal recessive disorder AADC deficiency, an early onset inborn error in neurotransmitter metabolism which can lead to catecholamine and serotonin deficiency.
-
References
- Ichinose, H. et al.,1989,Biochem. Biophys. Res. Commun. 164: 1024-1030.
- Lisa, J. S. et al., 1992, Genomics 13: 469-471.
- Moore, P. S. et al.,1996, Biochem. J. 315:249-256.
- Bertoldi, M. et al., 2003, Biochim. Biophys. Acta. 1647:42-47.
- Vassilacopoulou, D. et al., 2004, Neurochem. Res. 29: 1817-1823.
- Ma, J.Z., et al., 2005, Hum. Mol. Genet. 14: 1691-1698.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"